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Abstract
Background: Ankrd2 (also known as Arpp) together with Ankrd1/CARP and DARP are members of the MARP
mechanosensing proteins that form a complex with titin (N2A)/calpain 3 protease/myopalladin. In muscle, Ankrd2 is
located in the I-band of the sarcomere and moves to the nucleus of adjacent myofibers on muscle injury. In myoblasts it is
predominantly in the nucleus and on differentiation shifts from the nucleus to the cytoplasm. In agreement with its role as a
sensor it interacts both with sarcomeric proteins and transcription factors.
Methodology/Principal Findings: Expression profiling of endogenous Ankrd2 silenced in human myotubes was undertaken
to elucidate its role as an intermediary in cell signaling pathways. Silencing Ankrd2 expression altered the expression of
genes involved in both intercellular communication (cytokine-cytokine receptor interaction, endocytosis, focal adhesion,
tight junction, gap junction and regulation of the actin cytoskeleton) and intracellular communication (calcium, insulin,
MAPK, p53, TGF-b and Wnt signaling). The significance of Ankrd2 in cell signaling was strengthened by the fact that we
were able to show for the first time that Nkx2.5 and p53 are upstream effectors of the Ankrd2 gene and that Ankrd1/CARP,
another MARP member, can modulate the transcriptional ability of MyoD on the Ankrd2 promoter. Another novel finding
was the interaction between Ankrd2 and proteins with PDZ and SH3 domains, further supporting its role in signaling. It is
noteworthy that we demonstrated that transcription factors PAX6, LHX2, NFIL3 and MECP2, were able to bind both the
Ankrd2 protein and its promoter indicating the presence of a regulatory feedback loop mechanism.
Conclusions/Significance: In conclusion we demonstrate that Ankrd2 is a potent regulator in muscle cells affecting a
multitude of pathways and processes.
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Introduction
For any cell it is important to respond to external stimuli as
quickly and efficiently as possible, this is especially true for striated
muscle cells that are subjected to a variety of stress on a continuous
basis. In striated muscle focal points for mechanotransduction are
found at the Z-disc, the Z-disc/I-band interface and the M-band,
the link between them being the giant protein titin that spans the
sarcomere from the Z-disc to the M-band [1]. A signal complex
sensitive to mechanical stress (such as stretch and muscle injury) is
located at the I-band of the sarcomere and assembled on the N2A
region of titin. Titin serves as a scaffold for the organization of the
signal complex composed of myopalladin, calpain 3 and the
muscle ankyrin repeat proteins (MARPs) [1,2]. The MARP family
of proteins is composed of Ankrd1/CARP [3,4,5], Ankrd2 [6,7]
also known as ARPP [8] and DARP [9]. These proteins are
located at the Z/I band interface and are expressed both in
cardiac and skeletal muscle, however Ankrd1/CARP is expressed
primarily in cardiac muscle [3,4,5] and Ankrd2 mainly in skeletal
muscle [6,7,8]. The MARPs have several important functional
domains: ankyrin repeats involved in protein-protein interaction,
PEST motifs that are regions of protein instability and putative
nuclear localization signal (NLS) for sorting proteins into the
nucleus [1].
To study the role of the MARP proteins in skeletal muscle
Barash and colleagues produced mice with either single, double or
triple knockouts of these members [10]. However these animals
showed only minor differences in fiber size and type compared to
wild type mice, with a trend towards a slower fiber-type distri-
bution. In triple knockout mice, after eccentric contractions, slight
differences in mechanical behavior were observed, and both
MyoD and muscle LIM protein were up-regulated [10]. Although
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mpn.gov.rs/).  TheMARP knockout mice showed a relatively mild phenotype, the
MARP proteins are important for normal function of striated
muscle. In fact, Ankrd1/CARP mutations have been implicated in
dilated cardiomyopathy (DCM) probably due to the disruption of
its binding to Talin-1 and FHL2 (four and a half LIM domains 2)
which could cause dysfunction of the cellular stretch-based
signaling machinery [11]. Also Ankrd2 expression is altered in
some skeletal muscle disorders: it is down-regulated in patients
with muscular dystrophy, while up-regulated in atrophic or
damaged myofibers in patients with congenital myopathy. In
spinal muscular atrophy Ankrd2 is induced in hypertrophic
myofibers and Ankrd2–positive myofibers are arranged in groups
as a result of the process of denervation [12].
Ankrd2 is thought to have dual, structural and signaling roles,
and could link the elastic I-band region as a stress sensor for
transcriptional control in the nucleus. Its stretch sensor function
has already been demonstrated [6] and notably, in skeletal muscle
it is strongly up-regulated under acute stress such as muscle stretch
[6], injury [13], denervation [14] and differentiation [7,15]. After
muscle injury Ankrd2 accumulated in the nuclei of myofibers
adjacent to the damaged ones [13]. Ankrd2 can also be found in
the nucleus of proliferating myoblasts where it may regulate the
expression of specific target genes by acting as a transcriptional co-
factor since it binds to and modulates the activity of transcription
factors (TFs) p53, YB-1 and PML [15]. It has been suggested that
the modulator protease calpain 3 regulates sarcomeric localization
of MARPs and their interactions with other proteins of the
signaling complex. Both Ankrd1/CARP and Ankrd2 are digested
by calpain 3 [2,16] and as demonstrated for Ankrd1/CARP
calpain 3-mediated cleavage strengthens its interaction with titin
N2A region [16]. Apart from titin and calpain 3, Ankrd2 also
interacts with the Z-disc protein telethonin that enables precise
and rigid anchoring of titin within the sarcomere [15].
Currently, little is known about muscle specific regulation of
Ankrd2 expression. Bean and colleagues have shown that Ankrd2
expression is induced by MyoD, a key regulator of myogenic
differentiation [17]. Ankrd2 contributes to the coordination of
proliferation and apoptosis during myogenic differentiation in vitro,
possibly via the p53 network, as p53-activated apoptosis was
promoted in C2C12 myoblasts overexpressing Ankrd2. Also, both
MyoD and late markers of differentiation were downregulated
whereas Ankrd2 silencing resulted in proliferation of mouse
myoblasts [18]. Recently, Mohamed and colleagues demonstrated
that, depending on the stretch direction, Ankrd2 expression could
be up-regulated either by activation of the NFkB or AP-1 signaling
pathways [19]. The transcription factor nuclear factor-kappaB
(NF-kB) is particularly interesting since it is activated by
mechanical stretch [20] and implicated in regulation of muscle
atrophy. Recently, Ankrd1/CARP was identified as indirect target
gene of two transcription factors p50 and Bcl-3, shown to be
required for muscle disuse atrophy [21]. The classical NF-kB
pathway has a role in skeletal muscle cells differentiation and acts
to prevent their premature differentiation [22].
The localization of Ankrd2 in the I-band of muscle as part of a
putative mechanosensing complex [1], its accumulation in the
nucleus after muscle injury [13] and in proliferating myoblasts
[15], together with its interaction with transcription factors (p53,
YB-1 and PML) [15] and its localization in euchromatin [13],
strongly supports Ankrd2 role in the regulation of gene expression.
The aim of this work was to discover pathways in which Ankrd2
has a pivotal role by identifying potential targets of Ankrd2, as well
as regulators of Ankrd2 expression to bridge current gap in
knowledge related to Ankrd2 biological functions and its
regulatory role in muscle.
Results
In order to discover the cellular networks and pathways in
which Ankrd2 plays an active role, we employed microarray
technology to look at the gene expression profile in primary
human myotubes after silencing Ankrd2 using RNA interference.
Expression profiling of endogenous Ankrd2 silenced
myotubes
To determine genes and ultimately pathways affected by
silencing Ankrd2 in human differentiated muscle cells we used a
strategy exploiting Adeno–associated viruses as detailed in the
Experimental Procedures section. This strategy was used as
differentiated muscle cells are notoriously difficult to transfect.
To identify the Ankrd2 related genes involved in the crucial steps
of the myogenic program a series of DNA microarray experiments
were performed using total RNA from silenced and non-silenced
human skeletal muscle cells (CHQ5B). In cells infected with AAV-
shRNAex1-2 (S) the endogenous Ankrd2 is significantly reduced
both at the RNA and protein level compared to its levels in non-
silenced cells infected with AAV-shLuc (N) and uninfected control
cells (C) (Figure S1).
Alterations in the transcriptional profile of Ankrd2-silenced cells
compared to non-silenced cells were determined using the Whole
Human Genome Oligo Microarray system (Agilent Technologies).
The data were analyzed using several tools for data filtering and
normalization in order to select a discrete number of differentially
regulated genes with a threshold level for False Discovery Rate
(FDR) 0%. Normalized expression values were used as input for
the Significance Analysis of Microarray (SAM) software. Setting
the delta value at 1.212, the FDR of the selected genes was equal
to zero and after removing genes represented in the array by more
than one spot and false genes SAM extracted 1,891 significantly
differentially expressed genes. Expression value ratios (S/N)
between the two channels are given as a logarithmic scale base
2 (log2). A threshold for differential expression of log2 ratio .0.8 or
,20.8 was used giving 732 single genes selected by SAM in
silenced cells. However after removing genes not noted in the
human gene database GeneCards v3 (http://www.genecards.org/),
599 single genes were selected of which 281 were under-expressed
(Table S1) and 318 were over-expressed (Table S2). As expected the
Ankrd2gene wasoneofthemost significantlydown-regulated genes
with a log2 ratio equal to -2.02 (Table S1).
How much is gene expression altered by infection per se? In
order to evaluate the impact of infection on the behaviour of
skeletal muscle cells, hybridization experiments between non-
silenced cells infected with AAV-shLuc and uninfected cells were
performed under the same conditions as previously used for
silenced versus non-silenced cells. From SAM analysis there was
no marked difference between these conditions, in fact with a FDR
0% and after the elimination of repeated genes there were only 13
genes with a significant change in expression (log2 ratio values
,22.5). The complete list of significantly changed genes,
including those identified with a higher FDR value of 5% is
reported in Table S3. The vast majority of these genes are related
to cell cycle or mechanisms for DNA repair and replication.
To obtain an overall view of the effect of silencing Ankrd2 in
human myotubes on cellular pathways the differentially expressed
genes (Tables S1 and S2) were checked by the KEGG pathway
database (http://www.genome.jp/kegg/pathway.html) using the
Homo sapiens reference pathway. Only pathways with more than
7 differentially expressed genes have been listed in Tables 1 and S4
but in fact many more pathways were detected by KEGG. Table
S4 lists not only the genes differentially expressed in the various
Role of Ankrd2 in Signaling
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and log2 ratio, whereas Table 1 is a reduced form of this
information only listing gene symbols and if up- and down-
regulated. The 18 pathways with at least 7 differentially expressed
genes are listed in Tables 1 and S4, in brackets are the number of
genes whose expression has changed in each pathway: Metabolic
(34); Cancer (17); Focal adhesion (14); MAPK signaling (13);
Cytokine-cytokine receptor interaction (12); Regulation of the
actin cytoskeleton (12); Insulin signaling (12); Wnt signaling (10);
Calcium signaling (9); Gap junction (9); Hypertrophic cardiomy-
opathy, HCM (8); Dilated cardiomyopathy, DCM (7); Chronic
myeloid leukemia (7); Endocytosis (7); Huntington’s disease (7);
p53 signaling (7); TGF-b signaling(7) and Tight junction (7).
As seen in Tables 1 and S4 several signaling pathways were
affected by silencing Ankrd2 in myotubes therefore to further
investigate the regulatory role of Ankrd2 in skeletal muscle cells,
we screened for proteins that interact with Ankrd2 and that could
participate in signaling pathways.
Ankrd2 can interact with PDZ-motif and SH3 domain
proteins involved in signaling pathways
The results obtained from Ankrd2 silencing in human myotubes
suggesting its role in intracellular and intercellular communication
strongly corroborate a regulatory role for Ankrd2 as participant in
signaling pathways. Therefore we choose to screen for PDZ and
SH3 proteins as they are known to be involved in signaling
pathways [23] and recently the PDZ-Lim protein family has been
reported to mediate signals from the nucleus to the cytoskeleton
[24]. Both PDZ and SH3 domains are conserved and act as
modules for protein-protein interactions. Ankrd2 contains ankyrin
repeats important for protein-protein interactions, therefore we
hypothesized that Ankrd2 could interact with regulatory factors
that also contain other types of modules for protein-protein
interactions.
In order to identify regulatory proteins that physically interact
with Ankrd2 we screened PDZ domain protein arrays (Panomics/
Affymetrix, USA) with His-tagged Ankrd2 protein (Figure 1). The
Table 1. KEGG pathways differentially expressed in Ankrd2 silenced myotubes.
KEGG pathways Upregulated genes Downregulated genes
hsa01100
Metabolic pathways
B3GALT4, CBS, DHRS3, GBE1, GCS1, KHK, NDST1, NDUFC2,
PCK2, PLCB4, PNPLA3, POLR2K, SCA4MOL, SQLE, UAP1
ADSSL1, AKR1B10, AMPD1, AMY1C, ATP6V1E2, BCAT1,
CKM, CYP27A1, GCNT3, GLUL, HADH, MLYCD, PFKM,
PIK3C2B, PLCD4, PPT1, SPTLC3, ST8SIA5, TRIT1
hsa05200
Pathways in cancer
ITGA6BCR, CCND1, CDK6, FGF2, JUP, MAP2K1, PDGFB,
PDGFRB, RUNX1, TFG, TGFB2
ARNT, CYCS, EGLN3, FZD4, LAMA4
hsa04510
Focal adhesion
ACTB, ACTN4, CAV1, CCND1, CCND2, FLNB, ITGA6,
MAP2K1, PDGFB, PDGFRB, SHC2
ITGB8, LAMA4, MYL5
hsa04010
MAPK signaling
BDNF, FGF2, FLNB, GADD45B, MAP2K1, MAP3K7,
MKNK2, NTF3, PDGFB, PDGFRB, TGFB2
MEF2C, RPS6KA5
hsa04060
Cytokine-cytokine
receptor interaction
CCL2, EPOR, NGFR, PDGFB, PDGFRB, TGFB2,
TNFRSF11B, TNFRSF12A, TNFRSF25
ACVR1, IL17B, IL6R
hsa04810
Regulation of actin
cytoskeleton
ACTB, ACTN4, ARHGEF4, ARPC1B, BAIAP2,
FGF2, ITGA6, MAP2K1, PDGFB, PDGFRB
ITGB8, MYL5
hsa04910
Insulin signaling
MAP2K1,MKNK2, PCK2, PRKAA2, PRKAG2,
PTPRF, PYGB, SHC2
PHKG1, PPARGC1A, PYGM, RPS6KB1
hsa04310
Wnt signaling
CCND1, CCND2, MAP3K7, NFAT5, PLCB4, SFRP4 DAAM1, FRAT2, FZD4, MMP7
hsa04020
Calcium signaling
ADRA1B, ADRB2, PDGFRB ADCY3, ATP2A1, PHKG1
hsa04540
Gap junction
MAP2K1, PDGFB, PDGFRB, PLCB4, TUBB, TUBB3, TUBB8 ADCY3, TUBA8
hsa05410
HCM
ACTB, EMD, ITGA6, PRKAA2, PRKAG2, TGFB2, TPM1 TTN
hsa05414
DCM
ACTB, EMD, ITGA6, TGFB2, TPM1 ADCY3, TTN
hsa05220
Chronic myeloid
leukemia
BCR, CCND1, CDK6, MAP2K1, RUNX1, SHC2, TGFB2
hsa05016
Huntington’s disease
BDNF, NDUFC2, PLCB4, POLR2K CYCS, Dynein, PPARGC1A
hsa04115
p53 signaling
CCND1, CCND2, CDK6, GADD45B, IGFBP3, SERPINE1 CYCS
hsa04350
TGF-beta signaling
CHRD, GDF6, SMURF2, TGFB2 ACVR1, PITX2, RPS6KB1
hsa04530
Tight junction
ACTB, ACTN4, RAB3B, YES1 MYH8, MYL5, TJP2
doi:10.1371/journal.pone.0025519.t001
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e25519Figure 1. Ankrd2 can bind proteins via their PDZ domain. Panels (A), (B), (C) and (D) show respectively PDZ arrays I, II, III and IV (Panomics/
Affymetrix, USA) probed with His-tagged Ankrd2 (15 mg/ml). On the left are diagrams showing of the positions of the GST-PDZ proteins on the
membrane; PDZ proteins that interact with Ankrd2 are highlighted. On the right are the membranes after probing with His-Ankrd2: (A) on PDZ array I
a very strong positive signal was detected for the Reversion-induced LIM protein (RIL); weak positive signals for the PDZ and LIM domain protein 1
(hCLIM1) and Discs large homolog 4 (Dlg4). (B) on PDZ array II positive signals were detected for domain 1 and 2 of Zonula occludens (ZO-1 and ZO-
2). (C) on PDZ array III positive signals were detected for syntenin-2 beta, domain 2 (SDB2-D2); for partitioning-defective 3 homolog, domain 3 (PARD-
3) and for Scribble domain 4 (SCRIB1-D4). (D) on PDZ array IV positive signals were detected for domains 6 and 13 of the MUPP1 protein (MPDZ,
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of the binding affinity. In In Figure 1 on the left, are diagrams
showing of the positions of the GST-PDZ proteins on the
membrane; the PDZ proteins that interact with Ankrd2 are
highlighted. On the right are the membranes after probing with
His-Ankrd2. The following proteins bound strongly to Ankrd2:
RIL, Reversion-induced LIM protein (Figure 1A, row D 3/4);
ZO-1 D1 and ZO-1 D2, Zonula occludens (ZO) proteins
(respectively, Figure 1B, row D 3/4 and row D 5/6); SDB2-D2,
domain 2 of syntenin-2 beta (Figure 1C, row D 11/12); MUPP1-
D6 and MUPP1-D13, domain 6 and 13 of the multiple PDZ
domain protein (Figure 1D, row A 1/2 and 9/10); SNB1, Beta-1-
syntrophin (Figure 1D, row D 5/6); RIM2, regulating synaptic
membrane exocytosis 2 (Figure 1D, row E 1/2). Weaker positive
signals could be detected for: Dlg4-D3, Discs large homolog 4,
domain 3 (Figure 1A, row B 3/4); hCLIM1, PDZ and LIM
domain protein 1 (Figure 1A, row C 7/8); KIAA0316, FERM and
PDZ domain containing 4 (Figure 1B, row A 5/6); SCRIB1-D4,
Scribble domain 4 (Figure 1C, row C 15/16); PARD-3,
partitioning-defective 3 homolog, domain 3 (Figure 1C, row D
3/4); DLG5-D1, Discs large homolog 5, domain 1 (Figure 1D, row
B 1/2).
From the protein array data seen in Figure 1B, the Ankrd2
protein is able to bind strongly to the PDZ domains D1 and D2 of
ZO-1. This interaction between Ankrd2 and ZO-1 was confirmed
using an in vitro binding assay in which GST-Ankrd2 was used to
pull-down radiolabeled ZO-1 obtained by in vitro transcription and
translation (IVTT). In Figure 2 the right panel shows that only
GST-Ankrd2 bound the IVTT ZO-1 not GST. Left panel
demonstrates that equal quantities of GST-Ankrd2 and GST were
used. This in vitro binding experiment (Figure 2) confirms the
interaction detected on the PDZ membrane array (Figure 1B)
between Ankrd2 and ZO-1. It is important to note that the
expression of tight junction protein TJP2 (ZO-2) is down-regulated
in Ankrd2 silenced cells (Table S1). Zonula occludens (ZO)
proteins, ZO-1 and ZO-2 also known as Tight Junction proteins
(TJP), are involved in the organization of epithelial and endothelial
intercellular junctions and form a link between the junction site
and the cytoskeleton by interacting directly with actin filaments
[25,26,27].
A large number of PDZ-containing proteins have been grouped
into families according to their different modular organization
[28]. It is very interesting that Ankrd2 can interact with
representatives from several of the PDZ-protein groups. RIL and
hCLIM are members of the Enigma/PDZ-LIM family containing
a N-terminal PDZ domain and one or three LIM domains. Dlg
and ZO-1 are members of the MAGUK family that contain one
or three PDZ domains, a SH3 domain and GUK (guanylate
kinase) domain. Multi-PDZ-domain proteins, as the name
suggests, contain only multiple PDZ domains. Ankrd2 can bind
to MUPP1, a multiple PDZ domain protein with 13 PDZ
domains, which is located at tight junction and binds to the tight
junction claudins [29].
Src homology 3 (SH3) domain is a 60 amino acid protein
domain that mediates protein-protein interactions by binding to
proline-rich peptide sequences [30]. It is found in a large number
of proteins including cytoskeletal and many intracellular signaling
protein families such as the P13 kinase, Ras GTPase, CDC24 and
CDC25. Computer analysis (SH3-Hunter, http://cbm.bio.uniroma2.
it/SH3-Hunter/) predicted two overlapping regions (aa 107–113 and
aa 110–115) of the Ankrd2 protein able to interact with SH3 domains.
In order to confirm this finding a SH3 Domain Array (Panomics/
Affymetrix, USA) spotted in duplicate with 38 different SH3 domain
proteins was probed with His-tagged Ankrd2 protein (Figure 3).
Strong positive signals were detected for the following proteins:
Cortactin (row A 7/8); CRK-D2, sarcoma virus CT10 oncogene
homolog, domain 2 (row A 19/20); Y124, PAK-interacting exchange
factor beta (row C 5/6); PEXD, Peroxisomal membrane protein
PEX13 (row C 7/8); Stam, Signal transducing adaptor molecule (row
C1 9 / 2 0 ) ;P L Cc, Phospholipase C gamma-1 (row D 5/6). Weaker
interactions with Ankrd2 and SH3 proteins were also detected,
however in order to avoid false positives only the strong signals were
considered significant. Ankrd2 interacting partners containing PDZ
and SH3 domains are listed in the Table 2.
Ankrd2 is able to interact with several transcription
factors
Apart from participation in signaling pathways, Ankrd2 protein
has also been suggested to regulate transcription. In fact we
previously demonstrated that the Ankrd2 protein can bind three
transcription factors, p53, YB-1 and PML [15]. In order to
determine if other transcription factors were able to bind Ankrd2,
we used a TF array (TransSignal Transcription Factor Protein
Array II, Panomics/Affymetrix, USA) to screen for interaction
with GST-tagged Ankrd2 protein (Figure 4). The upper panel is a
schematic diagram showing the positions of 46 His-tagged
transcription factors spotted in duplicate on the membrane. The
lower panel shows the TF protein-protein array membrane after
probing with GST-Ankrd2 protein. Ankrd2 bound strongly to
several transcription factors: HAND2, heart and neural crest
derivatives expressed 2 (row A 1/2); HDC1, known as HDAC1
histone deacetylase 1 (row A 3/4); HOXA5, homeobox A5 (row A
5/6); HEY, hairy/enhancer-of-split related with YRPW motif 1
(row A 7/8); Jun, v-jun sarcoma virus 17 oncogene homolog (row
Multi-PDZ domain protein); for domain 1 of Discs large homolog 5 (DLG5-D1); for syntrophin 2 (SNTB1) and also for RIM2 (RIMS2). His-tagged ligand
was spotted in duplicate along the bottom and right edge for alignment and as a positive control.
doi:10.1371/journal.pone.0025519.g001
Figure 2. Ankrd2 interacts with tight junction protein ZO-1
(TJP1). The left panel shows GST-Ankrd2 pull down of radiolabeled ZO-
1: only the GST-Ankrd2 bound to ZO-1 and not GST protein alone. GST
or GST-Ankrd2 bound to glutathione-Sepharose 4B and was incubated
for 3 h at RT with IVTT
35S ZO-1. Immobilized complexes were then
washed and subjected to SDS-PAGE. The input was 10% of the total
amount of IVTT
35S-ZO-1 was used in each binding reaction. In the right
panel a SDS-PAGE gel stained with Coomassie blue shows that equal
amounts of GST-Ankrd2 and GST were used in this experiment.
doi:10.1371/journal.pone.0025519.g002
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like factor 12 (row B 7/8); LDB1, LIM domain binding 1 (row B
11/12); LHX2, LIM homeobox 2 (row B 13/14); MeCP2, methyl
CpG binding protein 2 (row C 5/6); NFIL3, nuclear factor,
interleukin 3 regulated (row C 21/22); PAX6, paired box gene 6
(row D 21/22). Weaker binding was seen between the Ankrd2
protein and the following TFs: HNF4G, hepatocyte nuclear factor
4, gamma (row A 9/10); MAFK, v-maf musculoaponeurotic
fibrosarcoma oncogene homolog K (row C 1/2); MAX, Myc
associated factor X (row C 3/4); NR1H2, nuclear receptor
subfamily 1, group H, member 2 (row D 7/8); p53, tumor
suppressor protein (row D 17/18). The list of Ankrd2 interacting
partners among transcription factors is given in the Table 2,the TF
proteins that bind both the Ankrd2 protein and promoter are
shown in bold. Although the Ankrd2-p53 protein interaction is
weak it can be taken as positive since it had previously been
confirmed by other methods [15]. However the other weak
interactions need further confirmation before being taken as
evidence of binding between Ankrd2 and these transcription
factors.
How does Ankrd2 interact with its binding partners?
The fact that Ankrd2 interacts with a variety of proteins,
differing both in function and cellular localization, raises the
question about mechanical aspect of these interactions. Possible
interaction sites are the five ankyrin repeats in its central region
since these motifs are known protein interaction sites [31]. We
previously demonstrated that Ankrd2 interacted with telethonin/
Tcap, p53, PML and YB-1 [15]; here we mapped their binding
sites on Ankrd2. GST pull down assays were performed by
incubating GST-Ankrd2 and its deletants with cell lysates
containing overexpressed recombinant PML, YB-1, telethonin/
Tcap and endogenous p53 from COS7 cells. A schematic diagram
showing the composition of the Ankrd2 protein (aa 5–333) and
Figure 3. Ankrd2 can interact with proteins containing SH3 domains. A SH3 protein array (Panomics/Affymetrix, USA) was probed with His-
tagged Ankrd2 protein (15 mg/ml). The upper panel is a schematic diagram of the array showing the positions of the spotted GST-proteins; proteins
positive for interaction with Ankrd2 are highlighted. The lower panel shows the membrane after hybridization with His-Ankrd2 protein. Ankrd2
bound strongly to the following SH3 proteins: Cortactin, CRK-D2, Y124, PEXD, Stam, and PLCc. The positive controls (in duplicate) intended for
alignment are seen at the bottom and the right edge of the blot.
doi:10.1371/journal.pone.0025519.g003
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terminus and ankyrin repeats (aa 5–284); CA, C-terminus and
ankyrin repeats (aa 121–333) and C, C-terminus (aa 280–333).
Figure S2 shows Coomassie stained gels of these proteins
demonstrating equal amounts of purified GST, GST tagged
Ankrd2 and its deletants used in the GST pull down reactions in
mapping experiments (Figure S2A corresponds to Figure 5B and
Figure S2B to Figure 5C).
Telethonin/Tcap binds full-length Ankrd2 and also the NA and
CA Ankrd2 fragments containing ankyrin repeats (Figure 5B)
indicating that interaction between the Ankrd2 and telethonin/
Tcap is mediated by the ankyrin repeats. Our results are in
agreement with those of Hayashi and colleagues [2]; they observed
a similar pattern for interaction between Ankrd2 and N2A region
of titin and suggested that the second ankyrin repeat is sufficient
for the Ankrd2-titin interaction. We propose that Ankrd2 is able to
accomplish its interaction with sarcomeric proteins via ankyrin
repeats and that these are sufficient to enable its participation in
building sarcomeric multiprotein complexes. However, as can be
seen in Figure 5B ankyrin repeats alone are not sufficient for
interaction with the transcription factors. In order to define the
specific binding sites at Ankrd2 N-terminus, a new construct sA (aa
98–333) was used. It contains ankyrin repeats and an adjacent N-
terminal 22 aa region. As demonstrated in Figure 5C, the sA
fragment can bind YB-1, PML and p53 suggesting that Ankrd2 N-
terminal binding domain for these proteins lies in the 98–121 aa
region.
Nkx2.5 and p53 are upstream effectors of the Ankrd2
gene but not NFkB
It is already known that a 280 bp of the Ankrd2 upstream region
is sufficient to confer muscle and temporal specific gene
expression [7]. However computer analysis of the Ankrd2
promoter region revealed several putative binding sites for
muscle specific (MyoD and Nkx2.5) as well as ubiquitous
transcription factors (p53 and NFkB). It has been demonstrated
that Ankrd2 gene expression is under the control of MyoD [17]. In
order to determine if Nkx2.5 and p53 could affect the Ankrd2
promoter, dual luciferase reporter gene assays were undertaken
using an Ankrd2 (2439/+7)-LUC reporter construct. C2C12
mouse myoblasts were transiently co-transfected with Ankrd2
(2439/+7)-LUC, the Renilla luciferase reporter plasmid and p53-
pCDNA3 or Nkx2.5-pCDNA3 expression vectors. The luciferase
activity driven by the Ankrd2 promoter increased in a dose-
dependent manner, when either Nkx2.5 (Figure 6A) or p53
(Figure 6B) was expressed.
To test whether NFkB has any influence on Ankrd2 promoter
activity, C2C12 myoblasts co-transfected with Ankrd2 (2439/+7)-
LUC and the Renilla luciferase reporter plasmids, were treated
with tumor necrosis factor (TNFa) for 20 h. This cytokine
activates NFkB and promotes its relocalization from the cytoplasm
to the nucleus. To check if NFkB was activated under conditions
used in dual luciferase assays, nuclear and cytoplasmic extracts
from C2C12 myoblasts grown in the presence of different
concentrations of TNFa (Figure 6D) were prepared. Subcellular
localization of NFkB subunit p50 was determined by Western blot
(Figure 6D). Equal amounts of nuclear and cytoplasmic extracts
were subjected to SDS PAGE, immunoblotted and probed with
anti-NFkB p50 and anti-histone H3 monoclonal antibodies; the
latter confirmed good separation of nuclear and cytoplasmic
proteins. p50 was detected exclusively in the nuclear extract;
moreover a dose dependent up-regulation of p50 expression is also
evident. Despite efficient activation of NFkB by TNFa,n o
difference in the relative luciferase activity driven from Ankrd2
promoter was detected between untreated and treated cells
(Figure 6C). The discrepancy between our results and those of
Mohamed and colleagues [19] could be explained by the fact that
we are using different model systems. Ankrd2 is upregulated by
NFkB in stretched mouse diaphragm muscle and is not a direct
target of p50 suggesting that additional factors are needed in order
to mediate NFkB dependent Ankrd2 expression [19]. We used
unstressed mouse myoblasts and an incomplete Ankrd2 promoter
therefore it is possible that additional elements are essential for
NFkB dependent regulation of Ankrd2 promoter activity. In
Table 2. Ankrd2 protein interactions detected by protein-
arrays.
Symbol Protein Description Pathway/Process
Transcription factors binding to Ankrd2
HAND2 heart/neural crest derivatives 2 NFAT/Cardiac hypertrophy
HDC1 histone deacetylase 1 Notch; Cell cycle; TGFb
HOXA5 homeobox A5 Skeletal development
HEY Hey1, hairy/enhancer-of-split Notch effector
HNF4G hepatocyte nuclear factor 4c Maturity onset diabetes
JUN transcription factor AP-1 MAPK
JUNB transcription factor AP-1 MAPK
KLF12 Kruppel-like factor 12 Vertebrate development
LDB1 LIM domain binding 1 Transcription reg. by Pitx2
LHX2 LIM homeobox 2 Nervous system develop.
MADH3 SMAD family member 3 Wnt signaling; TGFb
MAFK transcription factor MafK NRF2-med oxidative stress
MAX MYC associated factor X p38 MAPK
MECP2 MADS-box enhancer 2C MAPK; Cancer
MEF2C myocyte enhancer factor 2C MAPK
NFIL3 IL-3 regul. nuclear factor Immune response
NR1H2 nuclear receptor 1, H2 LXR/RXR activation
NR112 nuclear receptor subfam. 1 PXR/RXR activation
PAX6 paired box 6 MAPK/ERK
p53 tumor protein p53 MAPK; p53
PDZ domain proteins binding to Ankrd2
hCLIM1 PDZ and LIM domain 1 Regulation of transcription
DLG4 discs, large homolog 4 Nos1/Huntington’s disease
DLG5 discs, large homolog 5 Apoptosis; cell cycle
MUPP1 multiple PDZ domain Tight junctions
RIL PDZ and LIM domain 4 Actin stress fiber turnover
RIM2 reg. synaptic exocytosis 2 Intracell. protein transport
SDB2 syndecan binding protein 2 mTOR and NFAT pathways
SNB1 syntrophin, beta 1 nNOS signaling
ZO1 TJP1, tight junction prot.1 Tight and gap junctions
SH3 domain proteins binding to Ankrd2
CTTN Cortactin Tight junction
CRK proto-oncogene C-crk MAPK; Actin cytoskeleton
PEXD peroxisomal factor 13 Peroxisome
PLCc phospholipase C, gamma 1, ErbB; Calcium
STAM signal transducing adaptor 1 Jak-STAT; Endocytosis
Y124 ARHGEF7, Rho GEF 7 Actin cytoskeleton
doi:10.1371/journal.pone.0025519.t002
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able to modulate the Ankrd2 promoter in myoblasts.
The Ankrd2 promoter is able to bind several transcription
factors: Hand2, HOXA5, LHX2, MECP2, NFIL3, and PAX6
Eukaryotic gene expression is regulated by transcription factors
which are able to interact with specific DNA-binding elements
present in gene promoters in order to modulate transcription. The
activity of transcription factors is affected by a variety of factors
such as cell-type, tissue specificity and the phase of the cell cycle as
well as by interactions with other proteins. Knowing which
transcription factors bind to the Ankrd2 promoter will allow us to
understand how its expression is regulated.
In order to survey multiple transcription factors a protein/DNA
array was used (TransSignal Transcription Factor Protein Array
II, Panomics/Affymetrix, USA) which has 46 His-tagged tran-
scription factors spotted in duplicate on the membrane (Figure 7,
upper panel). We previously used an identical membrane to screen
for interactions between these transcription factors and Ankrd2
protein. To detect TF proteins that bind to theAnkrd2 promoter,
the promoter DNA (from 2 1,173 to 24 bp) was biotinylated, and
then used to probe the array. As can be seen in Figure 7 (lower
panel) transcription factors LHX2 (row B 13/14), MECP2 (row C
5/6), NFIL3 (row C 21/22) and PAX6 (row D 21/22) bound
strongly to the biotinylated DNA of the Ankrd2 promoter whereas
weaker binding was observed for Hand2 and HOXA5 (row A 1/2
and 5/6, respectively). It is interesting that these six transcription
factors listed in Table 3 also bound to the Ankrd2 protein (Figure 4,
lower panel and Table 2, shown in bold) which would suggest that
a feedback loop mechanism may be involved in controlling these
interactions.
Ankrd1/CARP modulates the transcriptional ability of
MyoD but not of Nkx2.5 on the Ankrd2 promoter
Similarly to Ankrd2 another MARP family member Ankrd1/
CARP has both structural and regulatory functions in striated
muscle, predominantly cardiac. Considering the regulatory role of
Ankrd1/CARP as a transcriptional cofactor, its expression in
skeletal muscle and the fact that recently Ankrd1/CARP was
shown to enhance the transcriptional ability of p53 on the Ankrd2
promoter [32] we examined whether it could modulate the effect
of MyoD and Nkx2.5 on Ankrd2 promoter activity. C2C12 mouse
myoblasts were transiently transfected with the reporter construct
Ankrd2 (2439/+7)-LUC, the Renilla luciferase reporter, p53-
pCDNA3 or Nkx2.5-pCDNA3 as well as increasing amounts of
the Ankrd1/CARP-pCDNA3 expression vectors. As can be seen
in Figure 8A, Ankrd1/CARP moderately increased the transcrip-
tional ability of MyoD emphasizing its positive effect on the Ankrd2
promoter. However Ankrd1/CARP expression did not affect the
Nkx2.5 mediated increase of Ankrd2 promoter activity (Figure 8B).
Discussion
In order to study the role of Ankrd2 in cell signaling pathways
we silenced endogenous Ankrd2 in human myotubes and
monitored gene expression by microarray analysis. Silencing
Ankrd2 expression affected genes involved in intercellular
communication (cytokine-cytokine receptor interaction, endocyto-
Figure 4. The Ankrd2 protein can interact with several transcription factors (TF). The upper panel is a schematic diagram of the
Transcription Factor Array II (Panomics/Affymetrix, USA) showing the positions of the spotted His tagged TF proteins. The lower panel shows the TF
protein-protein array membrane after probing with GST-Ankrd2 protein (15 mg/ml). The Ankrd2 protein bound very strongly to MeCP2 and strongly
to HAND2, HDAC1, HOXA5, HEY, JUN, JUNB, KLF12, LDB1, LHX2, NFIL3 and PAX6. Weaker binding was seen with HNFG4, MAFK, MAX, NR1H2 and p53.
The positive controls are at the bottom and right edge of the membranes. The TF proteins that interact with the Ankrd2 protein are highlighted.
doi:10.1371/journal.pone.0025519.g004
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the actin cytoskeleton) and intracellular communication (calcium,
insulin, MAPK, p53, TGF-b and Wnt signaling). Using protein
arrays we identified several interacting partners of Ankrd2; PDZ-
and SH3-containing proteins and transcription factors. Interest-
ingly, the TF proteins MeCP2, Pax6, NFIL3 and LHX2 bind both
to the Ankrd2 protein and Ankrd2 promoter DNA. Another novel
finding was that Nkx2.5 and p53 can act as upstream effectors of
the Ankrd2 gene and that Ankrd1/CARP can affect the
transcriptional ability of MyoD on the Ankrd2 promoter. From
the information obatined we can assert that Ankrd2 can act as a
powerful regulator in skeletal muscle cells, affecting a multitude of
pathways and processes including myogenesis, regulation of gene
expression, as well as intra- and intercellular signaling. It exerts its
function through interaction with transcription regulators, struc-
tural and signaling proteins. Our data are in favor of the proposed
function for Ankrd2 in transmitting and transforming mechanical
signals into cellular response.
From microarray profiling results, it is evident that alteration in
Ankrd2 expression can cause changes in the expression of genes
involved in several pathways identified using the KEGG database.
Most of the affected genes belong to metabolic pathways, which is
not surprising as muscle remodeling process in which Ankrd2 take
a part, demands also changes in supporting energy metabolism.
Apart from the collection of diverse metabolic pathways that had
no particular pathway affected, there are basically three main
groups of pathways with differentially expressed genes. The first
group is involved in intracellular communication and affects the
following signaling pathways: calcium, insulin, MAPK, p53, TGF-
b and Wnt signaling. The second group is that of intercellular
communication pathways affecting: cytokine-cytokine receptor
interaction, endocytosis, focal adhesion (FA), tight junction (TJ),
gap junction and regulation of the actin cytoskeleton. The third
group is that of disease pathways including Cancer, chronic
myeloid leukemia, Hungtington’s disease, DCM and HCM
cardiomyopathies.
In intracellular communication the majority of external signals
move into the cell via ion channels, G-proteins or enyzme linked
receptors. Silencing Ankrd2 affects genes in the Calcium pathway:
calcium behaves as a second messenger transmitting neuromus-
cular activity into changes in transcription via calcineurin,
calcium-dependent or calcium–calmodulin-dependent protein
kinases. Interestingly, in Ankrd2 silenced myotubes FATZ-1/
myozenin-1/calsarcin-2 [33,34,35], a calcineurin/NFAT regula-
tor [36] is down regulated (Tables 1 and S1) whereas FATZ-2/
calsarcin-1/myozenin-2 that affects fiber type composition by
blocking calcineurin/NFAT activity is upregulated (Tables 1 and
S2) [37].
Another important pathway affected by Ankrd2 silencing is the
MAPK pathway which is activated by exercise, environmental
stress as well as implicated in muscle growth and differentiation
[38,39]. The majority of the detected differentially expressed
genes of the MAPK pathway are upregulated upon Ankrd2
silencing (Tables 1 and S2). Also several TF proteins that interact
with the Ankrd2 protein (Table 2) are associated with the MAPK
pathway: CRK, JUN, p53, MEF2C, PAX6 and MeCP2. It is
noteworthy that PAX6 and MEPC2 can also bind the Ankrd2
promoter DNA indicating the presence of control by a feedback
loop mechanism.
It is interesting that one of the pathways affected by Ankrd2
silencing is the Insulin signaling pathway especially since DARP, a
MARP family member, is up regulated in type 2 diabetes and
thought to have a role in glucose uptake in muscle [40]. The
insulin receptor substrate 1 (IRS-1) plays a key role in transmitting
signals from the insulin and insulin-like growth factor-I receptor
(IGF-IR) to the PI3K/Akt and Erk/MAPK pathways. Cullin7,
one of the genes down regulated on silencing Ankrd2, is an E3
ubiquitin ligase that targets IRS-1 for degradation by the
proteasome [41] and an increase in the IGF-IR was found to
up-regulate Pax6 and glucagon which in turn activated the IRS-2/
Figure 5. Mapping the interaction sites for YB-1, p53, PML and
telethonin/Tcap on Ankrd2. (A) Diagram of Ankrd2 modular
structure and deletants used in GST pull-down experiments: A, almost
full length Ankrd2 protein (aa 5–333); sA, Ankrd2 protein with a 97 aa N-
terminal deletion (aa 98–333); N, N-terminal (aa 5–120); NA, N-terminal
plus ankyrin repeats (aa 5–284); CA, C-terminal plus ankyrin repeats (aa
121–333); C, C-terminal (aa 280–333). (B) and (C) GST pull down assays,
equal amounts of GST proteins, immobilized on glutathione Sepharose
(Figure S2) were mixed with cell extracts containing telethonin/Tcap,
YB-1, p53 and PML. The resins were washed, subjected to SDS-PAGE
and immunoblotted. Negative control is GST, positive controls (INPUT):
for telethonin, 1 mg of U2OS cell lysate; for endogenous p53, 500 ng of
COS7 cell lysate; for YB-1 500 ng of lysate of COS7 cell overexpressing
FLAG-YB-1; and for PML, 500 ng of lysate of COS7 cells overexpressing
FLAG-PML.
doi:10.1371/journal.pone.0025519.g005
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type 2 diabetes [42].
The intercellular pathways involving cell junctions are linked to
the regulation of the actin cytoskeleton and cell signaling
pathways. Focal adhesions act as multi-protein signaling complex-
es as well as having the structural role of linking membrane
receptors and the actin cytoskeleton. Gap junctions are an
important component of intercalated discs in cardiac muscle
[43] and are necessary for skeletal muscle differentiation [44].
Tight junctions, also known as zonula occludens, are important for
signaling [45]. TJ proteins ZO-1, ZO-2 and ZO-3 have PDZ and
SH3 domains and link the TJ transmembrane proteins to the actin
cytoskeleton [26]. Here we show that Ankrd2 can bind ZO-1
(Figure 2 and Table 2) and that ZO-2 (TJP2) is downregulated on
Ankrd2 silencing (Tables 1 and S1). It is interesting that both ZO-
1 [46] and Ankrd2 (Figure 3) can also bind the Src tyrosine-kinase
substrate, Cortactin.
Several potential new interactions were discovered by probing
arrays of PDZ, SH3 and transcription factor proteins with Ankrd2
(Figures 1, 2, 3, 4) corroborating its regulatory role. As can be seen
in Table 2 some of these proteins have roles in cell junction
(MUPP1, ZO1, cortactin) and signaling pathways such as TGF-b
(HDC1, MADH3), Wnt (MADH3), MAPK (JUN, JUNB,
MECP2, MEF2C, PAX6, p53, CRK) and NFAT (HAND2,
SDB2). RIL and hCLIM are members of the Enigma family of
PDZ LIM proteins that have been shown to interact with the
members of both the FATZ (calsarcin/myozenin) and myotilin
families of Z-disc proteins [47]. Also of note is the fact that Ankrd2
can bind to MUPP1, a multiple PDZ domain protein, known to
bind the tight junction claudins [29].
Apart from the role of Ankrd2 in intracellular signaling, our
results indicate a new role for Ankrd2 in intercellular signaling, in
transmitting and transforming mechanical signals into cellular
response. It could be hypothesized that Ankrd2 is implicated in
spreading stress signals through a strictly intracellular route as well
as an inside/outside path to the sarcolemma and back to the
nucleus through cell-surface receptor pathways. The results
obtained by DNA and protein arrays are in accordance and
strongly implicate Ankrd2 role in regulatory and signaling
processes.
It was demonstrated that tumor suppressor p53 has complex
and multilevel interaction with MARP family members Ankrd1/
Figure 6. Transcriptional regulation of the Ankrd2 promoter by Nkx2.5, p53 and NFkB. Both Nkx2.5 (A) and p53 (B) are upstream effectors
of Ankrd2 gene expression. C2C12 cells were transfected with Ankrd2 (2439/+7)-LUC and Renilla luciferase reporter plasmids along with increasing
amounts of expression vectors for Nkx2.5 and p53 as indicated. (C) Canonical NFkB does not affect Ankrd2 promoter activity. C2C12 were co-
transfected with Ankrd2 (2439/+7)-LUC and Renilla luciferase plasmids and 5 hrs after transfection cells were treated with increasing amounts of
TNFa in order to activate NFkB. In all of these experiments the firefly luciferase activity was normalized against the Renilla luciferase. The histograms
show the mean of at least three independent experiments; the bars indicate the standard deviation. *p,0.05 versus control sample. (D) C2C12 cells
were grown in the presence of 0.1, 1and 20 ng/ml of TNFa for 20 h and nuclear (NE) and cytoplasmic (CE) extracts prepared. Activation of NFkBb y
TNFa was confirmed by Western blot detection of NFkB subunit p50 in the nuclear extract (upper two panels). Efficiency of protein separation was
monitored by histone H3 subcellular localization (lower two panels).
doi:10.1371/journal.pone.0025519.g006
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expression and MARPs are able to modulate the activity of p53.
We have already shown their physical interaction on protein level,
ability of Ankrd1/CARP to modulate p53 transcriptional activity
on different promoters and potential p53 dependant regulation of
Ankrd1/CARP expression through upregulation of Ankrd1
promoter activity [15,32]. Here we show that Ankrd2 gene
expression can be regulated by p53 since it significantly increased
Ankrd2 promoter activity in luciferase assays (Figure 6B). Since in
adult muscle both p53 and Ankrd2 levels increase in response to
stress [6,48] it could be suggested that p53 probably acts on Ankrd2
gene expression in differentiated muscle cells that are exposed to
stress stimuli such as stretch. Our results implicate a novel role for
p53 in up-regulation of Ankrd2 gene expression and as common
regulator of MARP expression.
Alterations in interaction between Ankrd2 and p53, as well as
other players in p53 pathway could be involved in pathogenesis of
some tumors. In fact, the expression of Ankrd2 is elevated in a very
high percentage of rhabdomyosarcomas and its use as a potential
tumor marker for differential diagnosis of this soft tissue sarcoma
Figure 7. Ankrd2 promoter DNA can interact with some transcription factors that also interact with the Ankrd2 protein. The upper
panel is a schematic diagram of the Transcription Factor Array II (Panomics/Affymetrix, USA) showing the positions of the spotted His tagged TF
proteins. The bottom panel shows the TF protein array membrane after hybridization with the biotinylated DNA of the Ankrd2 promoter (21,173 to
24 bp). The Ankrd2 promoter DNA bound strongly to MeCP2, LHX2, NFIL3 and PAX6 and more weakly to HAND2 and HOXA5. The positive controls
are at the bottom and right edge of the membranes. The TF proteins that interact with the Ankrd2 promoter are highlighted.
doi:10.1371/journal.pone.0025519.g007
Table 3. Transcription factors binding to Ankrd2 promoter DNA.
Gene Symbol Protein Description Pathway
HAND2 Heart/neural crest derivatives 2 NFAT Cardiac hypertrophy
HOXA5 Homeobox A5 Skeletal development
LHX2 LIM homeobox 2 Nervous system development
MECP2 MADS-box enhancer 2C MAPK; Cancer
NFIL3 IL-3 regulatory nuclear factor Immune response
PAX6 Paired box 6 MAPK/ERK
doi:10.1371/journal.pone.0025519.t003
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Wnt in embryonal rhabdomyosarcomas the canonical Wnt/B-
catenin signaling pathway was down-regulated possibly due to
altered AP-1 [51]. Since both Wnt [52] and Ankrd2 [13] are up
regulated on skeletal muscle injury it is not surprising that several
genes of the Wnt pathway are affected by Ankrd2 silencing. Apart
from tumors, Ankrd2 could be linked to dystrophies and cardiac
diseases since some proteins from the FATZ (myozenin/calsarcin),
myotilin and Enigma families are differentially expressed in
Ankrd2 silenced myotubes (Tables 1, S1 and S2).
Ankrd2 has an active role in the processes that coordinate
proliferation and differentiation in muscle [18,53]. Our results
support the indispensable role of Ankrd2 in myogenesis by
demonstrating that Ankrd2 silencing alters genes involved in cell to
cell communication, which is very important in myogenesis. The
changes in gene expression and cell morphology that occur during
myogenic differentiation must be coordinated in a spatiotemporal
fashion and one of the ways to achieve this is through regulation of
these processes by cell-cell adhesion and resultant signaling [54].
Also, primary and secondary myoblast fusion processes require
cell-cell contact [55,56].
Ankrd2 interacts with a variety of proteins that have diverse
function (structural and regulatory) and contain ankyrin repeats,
modules for protein-protein interaction. Our results revealed that
Ankrd2 has distinct binding patterns for its interacting partners. It
uses exclusively ankyrin repeats for interaction with sarcomeric
proteins (titin and telethonin), whereas N terminal domain that
maps to aa 98–121 is also needed for its interaction with TFs
(PML, YB-1 and p53). There are several SH3 and PDZ binding
sites predicted by ELM [57] within the Ankrd2 N-terminus and
although PDZ domains predominantly bind short C-terminal
peptides they can also bind internal peptide sequences [58]. It is
possible that binding motif(s) located in the N-terminus stabilize
the interaction between Ankrd2 and regulatory proteins. On the
other hand, calpain 3 could be also involved in regulation of
Ankrd2 protein-protein interactions and its intracellular localiza-
tion. Both Ankrd2 and Ankrd1/CARP are the substrates of this
modulator protease as well as titin [2,16]. Since the cleavage site of
Ankrd2 by calpains is Arg 77 which is situated proximally from
NLS, there is also a possibility that calpain 3 mediated proteolysis,
apart from regulation of Ankrd2 and titin interaction, could also
introduce conformational changes into Ankrd2 protein that allow
differential binding of Ankrd2 to sarcomeric or regulatory
proteins.
These results and observations should be analyzed in a light of
the most recent result that Ankrd2 is found to be a downstream
target in Akt pathway as demonstrated by Cenni and colleagues
[59]. Akt-mediated signaling pathways are important in differen-
tiation, regeneration and hypertrophy of muscle [60,61]. It was
found that Ankrd2 is a novel substrate specific for Akt2 and that
oxidative stress triggers phosphorylation of Ankrd2 Ser 99 which
in turn induced nuclear translocation of Ankrd2. In fact, the site of
Ankrd2 phosphorylation Ser99 corresponds to Ser72 in the
Ankrd2 primary sequence reported under accession number
CAI14194.1 in which Arg77 is the site of calpain 3 proteolysis.
This finding sheds a completely different light on these results since
the sites are very close. Phosphorylation of Ankrd2 by Akt2
induces nuclear translocation of Ankrd2. The proteolysed Ankrd2
could bind more strongly to the N2A region of titin in a similar
way as demonstrated for Ankrd1/CARP [16]. As phosphorylation
and cleavage sites are separated by only 5 amino acids, it is
possible that phosphorylation and proteolysis are competitive
processes that can alter the inter-cellular distribution of Ankrd2.
We hypothesize that the phosphorylated pool of Ankrd2 is
predominantly located in the nuclei and that the proteolysed
Ankrd2 is sequestered by the titin N2A region located at the I-
band. In muscle cells that are in early phase of differentiation
(binucleated cells), as well as in normal muscle tissue, both nuclear
and cytoplasmic localization of Ankrd2 can be observed. Since it is
known that Ankrd2 expression in the nucleus increases with stress,
a possible mechanism could be that calpain 3 is not able to
proteolyse Ankrd2 when Ser72 is phosphorylated, therefore
Ankrd2 is not sequestered by the titin N2A region but is free to
move to the nucleus. Rationalization of these separate observa-
tions on Ankrd2 selective interactions, calpain proteolysis and
phosphorylation by Akt 2 kinase has yet to occur, but an
association with coordination of stress response could be a possible
link. The interrelation and interdependence between these three
phenomena is another open question.
Molecular mechanisms that regulate Ankrd2 gene expression and
its role in the heart are completely unknown. Here we demonstrate
that the cardiac specific transcription factor Nkx2.5 up-regulates
Figure 8. Ankrd1/CARP enhances the transcriptional ability of MyoD, but has no effect on Nkx2.5 induced up-regulation of the
Ankrd2 promoter. C2C12 were co-transfected with both Ankrd2 (2439/+7)-LUC and Renilla luciferase reporter plasmids as well as a constant
amount of MyoD-pCDNA3 (A) or Nkx2.5-pCDNA3 (B), along with increasing amounts of an expression vector for Ankrd1/CARP, as indicated. In each
assay the amount of total DNA used in transfections was kept constant by the addition of pCDNA3 vector. The firefly luciferase activity was
normalized against Renilla luciferase. The histograms show the mean of at least three independent experiments performed in triplicate; the bars
indicate the standard deviation. *p,0.05 versus control sample.
doi:10.1371/journal.pone.0025519.g008
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specific MARP family member, could regulate Ankrd2 expression
through activation of MyoD. Apart from the well established
critical role of the transcriptional activator Nkx2.5 in cardiac
morphogenesis [62], it also has a role in the regulation of cardiac-
specific gene expression in the adult heart. Its expression is
upregulated in response to hypertrophic stimulation which may
have implications in the transcriptional regulation of the cardiac
gene program in hypertrophied hearts [63]. In the adult heart,
Nkx2.5 also plays an important role in protecting the myocardium
against cytotoxic damage [64]. Nkx2.5 mediated regulation of
Ankrd2 expression in the heart could be the mechanism
underlying its role in cardiac signaling pathways activated upon
stress.
Although Ankrd1/CARP acts as negative co-factor in the
regulation of cardiac specific gene expression [4,65], we recently
showed that Ankrd1/CARP could behave as a positive regulator
of gene expression and modulate p53 activity on the p21, Mdm2
and Ankrd2 promoters [32]. Here we demonstrate that Ankrd1/
CARP also acts as positive regulator of MyoD activity on the
Ankrd2 promoter (Figure 8). Therefore, apart from p53 [32], we
have identified MyoD as another transcription factor whose
activity can be modulated by Ankrd1/CARP. Although MyoD is
known as a key regulator of skeletal muscle differentiation it was
only recently detected in cardiac muscle, in periarterial Purkinje
fibers [66]. Purkinje fibers are conduction cells located in the inner
ventricular walls and since Ankrd2 is expressed in the ventricles [8]
it is possible that the expression of Ankrd2 in cardiac muscle cells is
under the control of MyoD and that Ankrd1/CARP could up-
regulate MyoD dependant Ankrd2 expression in the heart. The
emerging role of Ankrd2 in cardiac muscle is further supported by
our finding that the HCM and DCM pathways are both affected
when Ankrd2 is silenced in myotubes. One of the promising lines
of future studies on Ankrd2 could be to identify mutations in
Ankrd2 gene that are linked to these cardiomyopathies as has been
done for Ankrd1/CARP [11,67,68].
It is interesting that both the Ankrd2 promoter DNA and the
Ankrd2 protein can bind transcription factors MECP2, LHX2,
NFIL3 and PAX6 indicating the existence of a regulatory feedback
loop mechanism (Figures 4 and 7). Transcriptional regulators
HOXA5, KLF12 and LHX2 participate in developmental
processes and their interaction with Ankrd2 could be important
for its function in myogenesis. MECP2 is particularly interesting as
a nuclear protein with a role in gene regulation. Recently it has
been proposed to act not only as a transcriptional repressor but
also as an activator; in fact most genes appear to be activated
rather than repressed by MECP2 [69]. It should be noted that the
DNA of the Ankrd2 promoter that bound MECP2 was not
methylated, however MECP2 is also capable of binding non-
methylated DNA [70,71]. MECP2 is upregulated in differentiated
cardiomyocytes with a concomitant increase in global methylation
and condensed chromatin [72]. The finding that Ankrd2 binds
MECP2 suggests that Ankrd2 could affect not only transcription
but also chromatin remodeling. Therefore, the final target of
signaling cascades involving Ankrd2 could be the structural
modification of chromatin.
Conclusions
Our data support a multi-tasking role of Ankrd2 in many
cellular processes regulating skeletal muscle differentiation, growth
and remodeling. The results obtained from both the DNA- and
protein arrays give a strong indication that Ankrd2 represents a
central node within regulatory networks involved in the determi-
nation of muscle cells (MRF4), the regulation of trunk (SIX4,
MEF2C) and head (PITX2, LBD1) skeletal muscle formation,
control of muscle phenotype (MEF2, NFAT, JUNB, HDACs),
regulation of calcineurin activity (FATZs) as well as control of
muscle protein turnover (FOXO3A, PIK3C2B, NBR1, AKT
signaling, FATZs). As mechano-transcriptional links in the
myoblasts are found at distinct sarcomeric regions and activate
different transcriptional programmes it raises the question of
whether crosstalk between these pathways exists. Our data suggest
that the Ankrd2 protein, itself, represents a possible link between
distinct mechano-transcriptional connections. In fact, previous and
current results demonstrate its functional interaction with proteins
localized in the Z-disc (FATZ-1/myozenin-1/calsarcin-2, FATZ-
2/myozenin-2/calsacin-1, telethonin) and M-band (NBR1 and
MURFs) mechanosensing complexes. The functional significance
of crosstalk between different mechanosensors and synergistic or
antagonistic activation of transcriptional programmes that regulate
muscle remodeling remain to be elucidated.
Materials and Methods
Plasmid constructs
To express Ankrd2 and its deletants, the corresponding cDNAs
were inserted into the GST vector; pGEX-6P-3 (GE Healthcare).
These cDNAs coded for: the full-length Ankrd2 protein (A, aa 5–
333), the N-terminal (N, aa 5–120), the N-terminal with ankyrin
repeats (NA, aa 5–284), the C-terminal (C, aa 280–333), the C-
terminal with ankyrin repeats (CA, aa 121–333) and Ankrd2
lacking the first 97 amino acids (sA, aa 98–333). cDNAs for p53
and telethonin/Tcap were cloned into pCDNA3 (Invitrogen).
PML and YB-1 were cloned into a FLAG tag vector;
pCMVTag2B (Stratagene). The cDNAs for full-length Ankrd1/
CARP, Nkx2.5 and MyoD were amplified by RT-PCR from
human mRNA (Ambion), then cloned into pCDNA3. The
proximal promoter region of the Ankrd gene (2439/+7) was
amplified from human genomic DNA with primers, GCGACTC-
GAGGTACAGAACTGTCCTG and ATATAAGCTTCGCCT-
CTGCAGGCC, and cloned into the promoterless luciferase
reporter gene vector pGL4.1 (Promega).
Cell culture, transfections and preparation of protein
extracts
COS-7 (CRL-1651), U2OS (HTB96), SaOs2 (HTB-85) and
C2C12 (CRL1772) were obtained from the ATCC (Manassas,
VA, USA). COS-7 cells and C2C12 mouse myoblasts were
maintained in DMEM containing 10% (v/v) fetal calf serum (FCS)
and gentamycin (50 mg/mL) whereas U2OS and SaOs2 cells were
grown in the same medium but with 20% FCS. Primary human
myoblasts CHQ5B cells were obtained and grown as described
previously [33]. Differentiation medium was DMEM supplement-
ed with 0.4% Ultroser G (BioSepra Spa, France). Cells were
transfected using PolyFect (Qiagen), SuperFect (Qiagen) or
TransIT-LT1 (Mirus) according to the manufacturer’s protocols.
U2OS cells transfected with telethonin/Tcap were treated with
the proteosomal inhibitor MG132 (Sigma) two hours before
harvesting. Cells were harvested 24 hours after transfection,
washed and then lysed in buffer containing 50 mM Hepes
(pH 7.0), 250 mM NaCl, 0,1% (v/v) NP-40 and protease
inhibitors (Roche). In order to activate transcription factor NFkB,
C2C12 myoblasts were grown in the presence of 0.1, 1 and 20 ng/
ml of TNFa (Promega) for 20 h. Nuclear and cytoplasmic extracts
were prepared using ProteoJET
TM Cytoplasmic and Nuclear
Protein Extraction Kit (Fermentas) according to the manufactur-
er’s instruction.
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AdenoAssociated Virus (AAV) was used to deliver shRNA into
primary muscle cells during differentiation. The sequence of the
siRNA from Ankrd2 exon 1–2 that reduced the expression of
Ankrd2 protein in transfected COS-7 cells was used as a template
to design both sense and antisense oligonucleotides (21 nucleo-
tides). These were annealed and cloned as a ds oligo into the
pZAC2U62CMV2ZsGreen plasmid (a gift from Dr. Julie
Johnston, University of Pennsylvania, USA). The pZA-
C2U62CMV2ZsGreen plasmid contains a U6 promoter for
RNA polymerase III transcription of shRNA and a CMV
promoter for expression of the fluorescent protein ZsGreen as a
control of transfection or infection. The vector used for silencing
Ankrd2, AAV-shRNAex1-2, was prepared by the ICGEB
Telethon Core Facility, Trieste. Since Ankrd2 is upregulated on
differentiation it was necessary to infect already differentiating
CHQ5B cells (after 5 days differentiation) in order to have a good
level of endogenous Ankrd2 expression for silencing. Cells were
harvested 4 days after infection (total of 9 days differentiation).
Total RNA was extracted and analyzed by RT-PCR for Ankrd2
and GAPDH expression (Figure S1, two upper panels). The cell
lysates were analyzed by Western blot for expression of Ankrd2,
ZsGreen, Myosin Heavy Chain (MHC) and GAPDH (Figure S1,
lower four panels). GAPDH was used as a loading control, MHC
as an indicator of differentiation and ZsGreen as a control of
expression of AAV-shRNAex1-2. In cells infected with AAV-
shRNAex1-2 (S) the endogenous Ankrd2 is significantly reduced
both at the RNA and protein level compared to its levels in non-
silenced cells infected with AAV-shLuc (N) and uninfected control
cells (C).
Microarray experiments
For microarray experiments the conditions described above
were used; CHQ5B cells were differentiated in low serum for 5
days and then not infected or infected with AAV-shRNAex1-2 or
the control AAV-shLuc and harvested after 4 days of infection
(Figure S1). Total RNA samples were subjected to retro-
transcription with poly dT primers; cDNA was synthesized
incorporating Cy3- or Cy5-labeled CTP. The samples were mixed
(silenced with non-silenced cells and uninfected with non-silenced
cells) and hybridized to the oligos of the Whole Human Genome
Oligo Microarray (Agilent Technologies). After hybridization the
microarray slides were scanned for acquisition of fluorescence
intensity values. Total RNA from CHQ5B cells was used in seven
distinct hybridizations therefore for each spot on the array there
are 10 expression values (5 for silenced cells and 5 for non-silenced
cells) and the differential expression was obtained from the relative
abundance of hybridized mRNA. Raw expression data were
normalized with MIDAS software, a microarray data analysis
system (http://www.tm4.org/midas.html ) using the LOWESS
(Localized Weighted Smother Estimator) method. The raw
microarray data have been submitted to the MIAME ArrayEx-
press database (miamexpress@ebi.ac.uk) with accession number
E-MEXP-2949.
The normalized data were analyzed in order to select a discrete
number of differentially regulated genes with a threshold level for
False Discovery Rate (FDR) ,1%. Normalized expression values
were used as input for the Significance Analysis of Microarray
(SAM) software (http://www-stat.stanford.edu/,tibs/SAM/).
This software assigns a score to each gene based on the change
in gene expression relative to the standard deviation of repeated
measurements. For genes with scores greater than an adjustable
threshold (delta), SAM uses permutations of the repeated
measurements to estimate the percentage of genes identified by
chance, the FDR. Setting the delta value at 1.212, the FDR of the
selected genes was equal to zero and after removing genes
represented in the array by more than one spot and false genes
SAM extracts significantly differentially expressed genes. Expres-
sion value ratios (S/N and N/C) between the two channels were
then transformed to logarithmic scale base 2 (log2 ratio). Then
data analysis was the done using the KEGG database to find genes
affected in well known pathways.
GST pull-down assay and in vitro binding
GST-tagged recombinant proteins were expressed as detailed in
a previous paper [15]. Lysates were prepared from transfected
COS7 cells expressing PML or YB-1, and from transfected U2OS
cells expressing telethonin/Tcap. Untransfected COS7 cells were
used as a source of endogenous p53. Equal amounts of GST fusion
proteins immobilized on glutathione-Sepharose beads were
incubated from 2–12 hours at 4uC with cell lysate in binding
buffer: 50 mM HEPES (pH 7.0), 250 mM NaCl, 0.1% NP-40 and
protease inhibitors (Roche). Immobilized protein complexes were
washed with binding buffer and separated by SDS-PAGE. A
plasmid coding for human wild type ZO-1 was used as the
template for an IVTT reaction in the presence of [
35S] methionine
producing radiolabeled ZO-1. This protein was used in in vitro
binding assays with GST-Ankrd2 protein bound to glutathione-
Sepharose 4B or GST alone, incubated for three hours at RT,
washed and then subjected to SDS-PAGE.
Immunoblotting
Protein complexes, resolved by SDS PAGE, were transferred to
PVDF membrane (Immobilon P, Millipore) as previously reported
[14]. Proteins were visualized using the ECL chemiluminescence
detection system (Millipore). The primary antibodies anti-p53
(DO-1, Santa Cruz), anti-FLAG (M2, Sigma), anti-telethonin/
Tcap, anti-p50 (Santa Cruz) and anti H3 (Santa Cruz), as well as
secondary anti-mouse and anti-rabbit antibodies conjugated with
horseradish peroxidase (Sigma and Pierce, respectively) were used
for detection of p53, YB-1, PML, telethonin/Tcap, NFkB subunit
p50 and histone H3.
Protein arrays
PDZ and SH3 array membranes (Panomics/Affymetrix, USA)
were used according to the protocols in the manufacturer’s
handbook. His-tagged Ankrd2 protein (15 mg/ml) was used as a
ligand. The protein-protein and protein-DNA interaction assays
were carried out using the TransSignal Transcription Factor (TF)
Protein Array II (Panomics/Affymetrix, USA) according to the
manufacturer’s instructions. Briefly, purified Ankrd2-GST protein
or a DNA probe containing the Ankrd2 promoter region (21173 to
24 bp) amplified by PCR using biotinylated primers, were
incubated with TF protein array membranes. The interactions
were detected either using mouse anti-GST antibody and then
HRP-conjugated goat anti-mouse antibody (Sigma) to detect
GST-Ankrd2 bound to the spotted proteins on the membranes, or
streptavidin-HRP antibody, to detect the biotinylated DNA probe.
The signals were visualized by chemiluminescence.
Luciferase Assays
SaOs2 and C2C12 cells were grown for 24 h and then
transiently co-transfected with the reporter construct Ankrd2
(2439/+7)-LUC, expression vectors for p53, Nkx2.5, Ankrd1/
CARP or MyoD, and a control plasmid expressing Renilla
luciferase, pRL-TK (Promega). The total amount of DNA was
kept constant by the addition of empty vector; pCDNA3. In order
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0.1, 1 and 20 ng/ml of TNF a (Promega) for 20 h. The cells were
lysed in Passive Lysis Buffer (Promega) and luciferase activity was
measured using the Dual Luciferase Reporter Assay System
(Promega) according to the manufacturer’s instructions. The firefly
luciferase activity was normalized against Renilla luciferase and the
means of three independent experiments performed in triplicate
were calculated. Data were presented as means 6 standard error
of the mean. Individual means were compared using the Student t-
test. Differences were considered to be statistically significant at
p,0.05.
Supporting Information
Figure S1 Silencing of endogenous Ankrd2 in differen-
tiated human skeletal muscle cells, using an AdenoAs-
sociated Virus (AAV) vector AAV-shRNAex1-2. The
sequence of the siRNA from Ankrd2 exon 1–2 that reduced the
expression of exogenous Ankrd2 in transfected cells was used to
design both sense and antisense oligonucleotides (21 nucleotides).
These were annealed and cloned as a ds oligo into the
pZAC2U62CMV2ZsGreen plasmid that contains a U6 pro-
moter for RNA polymerase III transcription of shRNA and a
CMV promoter for expression of the ZsGreen fluorescent protein.
In order to have a good level of endogenous Ankrd2 expression for
silencing AAV-shRNAex1-2 was used to infect already differen-
tiating (after 5 days differentiation) primary human muscle cells
(CHQ5B). Cells were also infected with AAV-shLuc (N) as a
negative control. Cells were harvested 4 days after infection (total
of 9 days differentiation). Total RNA was extracted and analyzed
by RT-PCR for Ankrd2 and GAPDH expression (two upper
panels). The cell lysates were analyzed by Western blot for
expression of Ankrd2, ZsGreen, Myosin Heavy Chain (MHC) and
GAPDH (lower four panels). GAPDH was used as a loading
control, MHC as an indicator of differentiation and ZsGreen as a
control of expression of AAV-shRNAex1-2. In cells infected with
AAV-shRNAex1-2 (S) the endogenous Ankrd2 is significantly
reduced both at the RNA and protein level compared to its levels
in non-silenced cells infected with AAV-shLuc (N) and uninfected
control cells (C).
(TIF)
Figure S2 Coomassie blue stained gels demonstrating
equal amounts of purified GST, GST tagged Ankrd2 and
its deletants separated by SDS-PAGE. The same amounts of
proteins were used in GST pull down reactions in mapping
experiments, panel A corresponds to Figure 1B and panel B to
Figure 1C. Purified recombinant proteins are designated as: A,
almost full length Ankrd2 protein (aa 5–333); sA, Ankrd2 protein
with a 97 aa Nterminal deletion (aa 98–333); N, N-terminal (aa 5–
120); NA, N-terminal plus ankyrin repeats (aa 5–284); CA,C -
terminal plus ankyrin repeats (aa 121–333); C, C-terminal (aa
280–333). Molecular size of proteins is given on the left, in kDa.
(TIF)
Table S1 Genes downregulated in Ankrd2 silenced
myotubes.
(DOC)
Table S2 Genes upregulated in Ankrd2 silenced myo-
tubes.
(DOC)
Table S3 Differentially expressed genes in infected (non
silenced) compared to uninfected CHQ5B cells.
(DOC)
Table S4 KEGG pathways with 7 or more genes
differentially expressed in Ankrd2 silenced myotubes.
(DOC)
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